Yttrium-90 microspheres deliver local radiation as permanent brachytherapy implants to tumors in the liver.
MIM Software Wins FDA Nod for Post-Treatment Dosimetry of Yttrium-90 Microspheres |
| [26-November-2017] |
| CLEVELAND, Nov. 26, 2017 /PRNewswire/ -- MIM Software Inc., a leading global provider of medical imaging software, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for post-treatment dosimetry of Yttrium-90 (Y90) microspheres. Yttrium-90 microspheres deliver local radiation as permanent brachytherapy implants to tumors in the liver. Currently, PET or SPECT images are obtained after treatment to verify the distribution of microspheres. Now, absorbed dose from the Y90 microspheres can be calculated on a voxel-by-voxel basis using the PET or SPECT images. MIM SurePlan™ LiverY90 provides timesaving tools for liver and tumor segmentation, deformable registration, and allows patient-specific dose calculation on Y90 PET and Bremsstrahlung SPECT images after administration of permanent Y90 microsphere implants. The absorbed dose can be calculated for tumors and the liver to help provide important additional information to the clinician. Three methods are available for dose calculation: Local Deposition Model, Local Deposition Model with scaling for known injected activity, and the Voxel S Value approach based on the schema in MIRD Pamphlet No. 17. All three methods are available for PET while only the Local Deposition Model with scaling for known activity is available for SPECT images that are not in Becquerel per milliliter (Bq/ml). MIM Software will demonstrate MIM SurePlan LiverY90 at the 2017 Radiological Society of North America (RSNA) Annual Meeting November 26-30 in Chicago. Attendees wishing to view a demonstration can visit booth 8108. About MIM Software Inc. MIM Software Inc. provides practical imaging solutions in the fields of radiation oncology, radiology, nuclear medicine, neuroimaging, and cardiac imaging. MIM offers solutions for PC and Mac® workstations, mobile iOS and cloud-based platforms. MIM is a privately held company that sells its products globally to imaging centers, hospitals, specialty clinics, research organizations, and pharmaceutical companies. For more information, visit www.mimsoftware.com. View original content:http://www.prnewswire.com/news-releases/mim-software-receives-fda-510k-clearance-for-post-treatment-dosimetry-of-yttrium-90-microspheres-300560970.html SOURCE MIM Software Inc. |
